Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IONS - US4622221004 - Common Stock

77.53 USD
+1.2 (+1.57%)
Last: 1/20/2026, 8:00:02 PM
77.53 USD
0 (0%)
After Hours: 1/20/2026, 8:00:02 PM
Fundamental Rating

3

IONS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of IONS have multiple concerns. While showing a medium growth rate, IONS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year IONS has reported negative net income.
  • IONS had a negative operating cash flow in the past year.
  • In the past 5 years IONS always reported negative net income.
  • In multiple years IONS reported negative operating cash flow during the last 5 years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

  • IONS's Return On Assets of -8.45% is amongst the best of the industry. IONS outperforms 84.95% of its industry peers.
  • IONS has a better Return On Equity (-41.48%) than 70.29% of its industry peers.
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

  • IONS has a better Gross Margin (98.78%) than 98.10% of its industry peers.
  • IONS's Gross Margin has been stable in the last couple of years.
  • IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

  • IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IONS has been increased compared to 1 year ago.
  • The number of shares outstanding for IONS has been increased compared to 5 years ago.
  • The debt/assets ratio for IONS has been reduced compared to a year ago.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • IONS has an Altman-Z score of 2.67. This is not the best score and indicates that IONS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.67, IONS is doing good in the industry, outperforming 68.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.96 indicates that IONS is somewhat dependend on debt financing.
  • IONS has a Debt to Equity ratio of 0.96. This is in the lower half of the industry: IONS underperforms 74.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z 2.67
ROIC/WACCN/A
WACC8.3%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • IONS has a Current Ratio of 2.79. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
  • IONS has a worse Current ratio (2.79) than 66.67% of its industry peers.
  • A Quick Ratio of 2.78 indicates that IONS has no problem at all paying its short term obligations.
  • IONS's Quick ratio of 2.78 is on the low side compared to the rest of the industry. IONS is outperformed by 64.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.78
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.74% over the past year.
  • IONS shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.41%.
  • Measured over the past years, IONS shows a decrease in Revenue. The Revenue has been decreasing by -8.88% on average per year.
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%

3.2 Future

  • IONS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.46% yearly.
  • IONS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.79% yearly.
EPS Next Y24.18%
EPS Next 2Y-1.29%
EPS Next 3Y14.49%
EPS Next 5Y26.46%
Revenue Next Year44.9%
Revenue Next 2Y20.27%
Revenue Next 3Y29.42%
Revenue Next 5Y31.79%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IONS. In the last year negative earnings were reported.
  • Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • IONS's earnings are expected to grow with 14.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.29%
EPS Next 3Y14.49%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for IONS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (1/20/2026, 8:00:02 PM)

After market: 77.53 0 (0%)

77.53

+1.2 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)02-17
Inst Owners106.67%
Inst Owner Change-0.07%
Ins Owners0.72%
Ins Owner Change-8.46%
Market Cap12.56B
Revenue(TTM)966.96M
Net Income(TTM)-256.34M
Analysts81.38
Price Target89.78 (15.8%)
Short Float %9.26%
Short Ratio6.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)147.99%
Min EPS beat(2)36.42%
Max EPS beat(2)259.57%
EPS beat(4)4
Avg EPS beat(4)89.18%
Min EPS beat(4)18.36%
Max EPS beat(4)259.57%
EPS beat(8)8
Avg EPS beat(8)66.23%
EPS beat(12)11
Avg EPS beat(12)44.13%
EPS beat(16)14
Avg EPS beat(16)62.35%
Revenue beat(2)2
Avg Revenue beat(2)33.86%
Min Revenue beat(2)17.57%
Max Revenue beat(2)50.14%
Revenue beat(4)4
Avg Revenue beat(4)33.17%
Min Revenue beat(4)3.26%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)31.12%
Revenue beat(12)10
Avg Revenue beat(12)23.51%
Revenue beat(16)13
Avg Revenue beat(16)22.62%
PT rev (1m)4.88%
PT rev (3m)20.49%
EPS NQ rev (1m)-1.08%
EPS NQ rev (3m)-1.45%
EPS NY rev (1m)0.25%
EPS NY rev (3m)11.33%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)7.35%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)4.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.99
P/FCF N/A
P/OCF N/A
P/B 20.32
P/tB 20.32
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-3.12
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS5.97
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.45%
ROE -41.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.78%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1473.37%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.78
Altman-Z 2.67
F-Score5
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)219.39%
Cap/Depr(5y)190.33%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
EPS Next Y24.18%
EPS Next 2Y-1.29%
EPS Next 3Y14.49%
EPS Next 5Y26.46%
Revenue 1Y (TTM)20.41%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%17.16%
Revenue Next Year44.9%
Revenue Next 2Y20.27%
Revenue Next 3Y29.42%
Revenue Next 5Y31.79%
EBIT growth 1Y24.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.6%
EBIT Next 3Y21.55%
EBIT Next 5YN/A
FCF growth 1Y46.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.31%
OCF growth 3YN/A
OCF growth 5YN/A

IONIS PHARMACEUTICALS INC / IONS FAQ

What is the fundamental rating for IONS stock?

ChartMill assigns a fundamental rating of 3 / 10 to IONS.


What is the valuation status of IONIS PHARMACEUTICALS INC (IONS) stock?

ChartMill assigns a valuation rating of 0 / 10 to IONIS PHARMACEUTICALS INC (IONS). This can be considered as Overvalued.


What is the profitability of IONS stock?

IONIS PHARMACEUTICALS INC (IONS) has a profitability rating of 3 / 10.


What is the financial health of IONIS PHARMACEUTICALS INC (IONS) stock?

The financial health rating of IONIS PHARMACEUTICALS INC (IONS) is 3 / 10.